Akebia Therapeutics, Inc. Annual Cost of Revenue in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Akebia Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from 2018 to 2023.
  • Akebia Therapeutics, Inc. Cost of Revenue for the quarter ending September 30, 2024 was $14.2M, a 21.4% decline year-over-year.
  • Akebia Therapeutics, Inc. Cost of Revenue for the twelve months ending September 30, 2024 was $61.5M, a 16.4% increase year-over-year.
  • Akebia Therapeutics, Inc. annual Cost of Revenue for 2023 was $74.1M, a 13.3% decline from 2022.
  • Akebia Therapeutics, Inc. annual Cost of Revenue for 2022 was $85.6M, a 43.2% decline from 2021.
  • Akebia Therapeutics, Inc. annual Cost of Revenue for 2021 was $151M, a 49.2% decline from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $74.1M -$11.4M -13.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 $85.6M -$65.1M -43.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $151M -$146M -49.2% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-08-28
2020 $296M +$151M +104% Jan 1, 2020 Dec 31, 2020 10-K/A 2023-08-28
2019 $145M +$138M +1771% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $7.77M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.